MedTrace Logo

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

NCT01357356 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2020-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.

Conditions

  • Nocturia

Interventions

DRUG

SER120 (750 ng/day)

DRUG

SER120 (1000 ng/day)

SER120 (1000 ng/day)

DRUG

SER120 (1500 ng/day)

DRUG

Placebo

Sponsors & Collaborators

  • Serenity Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-10-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357356 on ClinicalTrials.gov